Memantine Hydrochloride Lupin

Memantine Hydrochloride, the active ingredient in Memantine Hydrochloride Lupin, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to reduce excitotoxic neuronal damage and support cognitive function. The product complies with European Union pharmaceutical standards and is manufactured under GMP conditions.

GNH USA supplies Memantine Hydrochloride Lupin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides regulatory documentation and supports import requirements for global distribution.

Memantine Hydrochloride is used in the management of Alzheimer’s disease, targeting glutamatergic neurotransmission to improve cognitive outcomes. - Moderate to severe Alzheimer’s disease: improves cognition, daily functioning, and behavioral symptoms in adult patients. - Combination therapy with cholinesterase inhibitors: enhances overall therapeutic effect when used alongside donepezil or rivastigmine. - Mild to moderate Alzheimer’s disease (off‑label in some regions): may support cognitive stability when other treatments are insufficient. - Behavioral disturbances associated with Alzheimer’s disease: may reduce agitation and aggression.

Memantine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Confusion: transient disorientation or difficulty concentrating.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythm. - Hallucinations: visual or auditory perceptual disturbances.

When prescribing Memantine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and use with caution. - History of seizures: observe for increased seizure activity. - Concomitant NMDA antagonists: avoid combined use to prevent additive neuro‑blocking effects. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at room temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Memantine Hydrochloride can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuro‑psychiatric side effects. - High‑dose potassium supplements: may alter renal excretion of memantine.

Moderate Interactions (Monitor Closely): - Cholinesterase inhibitors (e.g., donepezil, rivastigmine): monitor for additive cognitive effects. - Diuretics (e.g., furosemide): watch for changes in serum potassium levels. - CNS depressants (e.g., benzodiazepines): may enhance dizziness or sedation. - Cimetidine: may increase memantine plasma concentrations.